Rigel Pharmaceuticals Inc (RIGL)
14.20
+0.57
(+4.18%)
USD |
NASDAQ |
Nov 01, 16:00
14.12
-0.08
(-0.56%)
After-Hours: 20:00
Rigel Pharmaceuticals Enterprise Value: 260.44M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 260.44M |
| October 31, 2024 | 250.41M |
| October 30, 2024 | 261.67M |
| October 29, 2024 | 262.90M |
| October 28, 2024 | 266.07M |
| October 25, 2024 | 259.74M |
| October 24, 2024 | 264.49M |
| October 23, 2024 | 267.30M |
| October 22, 2024 | 272.05M |
| October 21, 2024 | 271.17M |
| October 18, 2024 | 276.45M |
| October 17, 2024 | 276.98M |
| October 16, 2024 | 285.60M |
| October 15, 2024 | 279.79M |
| October 14, 2024 | 276.63M |
| October 11, 2024 | 282.08M |
| October 10, 2024 | 278.56M |
| October 09, 2024 | 276.45M |
| October 08, 2024 | 286.83M |
| October 07, 2024 | 281.38M |
| October 04, 2024 | 292.81M |
| October 03, 2024 | 292.99M |
| October 02, 2024 | 302.49M |
| October 01, 2024 | 298.62M |
| September 30, 2024 | 295.28M |
| Date | Value |
|---|---|
| September 27, 2024 | 299.50M |
| September 26, 2024 | 292.11M |
| September 25, 2024 | 292.99M |
| September 24, 2024 | 298.27M |
| September 23, 2024 | 250.94M |
| September 20, 2024 | 252.70M |
| September 19, 2024 | 251.47M |
| September 18, 2024 | 250.41M |
| September 17, 2024 | 251.29M |
| September 16, 2024 | 252.52M |
| September 13, 2024 | 251.64M |
| September 12, 2024 | 238.45M |
| September 11, 2024 | 238.80M |
| September 10, 2024 | 236.69M |
| September 09, 2024 | 247.07M |
| September 06, 2024 | 244.96M |
| September 05, 2024 | 246.54M |
| September 04, 2024 | 242.49M |
| September 03, 2024 | 241.44M |
| August 30, 2024 | 247.07M |
| August 29, 2024 | 249.00M |
| August 28, 2024 | 237.57M |
| August 27, 2024 | 243.02M |
| August 26, 2024 | 247.24M |
| August 23, 2024 | 230.18M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
38.10M
Minimum
Jun 10 2022
797.94M
Maximum
Feb 08 2021
308.07M
Average
260.44M
Median
Nov 01 2024
Enterprise Value Benchmarks
| Ionis Pharmaceuticals Inc | 5.311B |
| Collegium Pharmaceutical Inc | 1.359B |
| NovaBay Pharmaceuticals Inc | 3.615M |
| Palatin Technologies Inc | 13.93M |
| iBio Inc | 9.837M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.03M |
| Revenue (Quarterly) | 36.84M |
| Total Expenses (Quarterly) | 36.39M |
| EPS Diluted (Quarterly) | -0.06 |
| Gross Profit Margin (Quarterly) | 92.38% |
| Profit Margin (Quarterly) | -2.80% |
| Earnings Yield | -5.35% |
| Normalized Earnings Yield | -5.352 |